SironRX Therapeutics

Business Website: http://www.sironrx.com/

SironRX was formed in December 2010 to develop regenerative medicine therapies that promote wound repair and prevent scarring of dermal wounds.

SironRX was formed in December 2010 to develop regenerative medicine therapies that promote wound repair and prevent scarring of dermal wounds. The company’s lead product, JVS100, uses the body’s natural tissue repair mechanism in a way that is thought to expedite the healing process and reduce scarring. It encodes Stromal cell-Derived Factor-1 (SDF-1), which is produced by the body in response to tissue injury and activates the natural repair processes to prevent cell death and recruit stem cells to the damaged organ. This process is applied in a way triggers the body to repair itself instead of introducing palliative products into the system.

The idea spun out of a technology in development at the Cleveland Clinic, whereby a similar methodology was being explored on heart conditions. The SironRX leadership team realized that this factor had many applications beyond the heart system, and sought private capital to develop and test the product.

The concept was intriguing to Zapis Capital because of its regenerative approach, and its potential to make a positive impact among millions of people. Zapis Capital invested in SironRX in 2011 to help fund the requisite research and trial required to bring the product to market.

JVS100 is currently in clinical studies to demonstrate its safety and efficacy.

Status: Former Portfolio